Clinical and preclinical studies not only provided basic evidence for the efficacy of Lp‐PLA2 inhibitors in the treatment of AD and DME but also elucidated specific mechanisms of action that were independent of the most studied risk factors, such as Aβ and VEGF. The gene discussed is VEGFA; the disease is Alzheimer disease.